Beijing BioBio has total assets of RMB 587 million as of the end of 2007, with 24,000 square meters of R&D, production and operation facilities, including GMP production workshops for clinical diagnostic-grade microarray chips and auxiliary reagents, microprocessing cleanrooms for silicon-based and plastic-based microfluidic chips, as well as workshops for the production of biochip-related instrumentation and equipment. The company has obtained the Drug Manufacturer License, Medical Device Manufacturer License and Medical Device Business Enterprise License from SFDA, the Laboratory Accreditation Certificate issued by China National Accreditation Service for Conformity Assessment (CNASC), and the ISO 9001, ISO 13485 and ISO 17025 quality management system and external service laboratory qualification certificates. BioBio has two wholly-owned overseas independent legal entities (BioBio Hong Kong Ltd. and BioBio International Ltd.), and two domestic and foreign holding companies (Aviva Biosciences Inc. and Shenzhen Microchip Bio-technology Co., Ltd.), with more than 400 employees, through patented technology and cash contributions.
The rapid development of BioBio has attracted a lot of attention. 2002, BioBio, as the only company in Asia, was named by Fortune Magazine as one of the "World's Most Promising Biotechnology Companies". 2003, BioBio was listed in the "New Economy Magazine", sponsored by the Development Research Center of the State Council, as one of the "Best Biotechnology Companies" in the world. In 2003, BioBio was ranked first in the list of "China's Top 10 Biochip Enterprises" by the New Economy Magazine sponsored by the Development Research Center of the State Council. In 2004, Fortune Magazine once again wrote an article stating that "BioBio has become China's first biotech company to enter the world's level of excellence"; In 2005, BioBio became one of the eight biotech companies in the "Asia's Top 100 Unlisted Technology Companies" selected by Red Herring Magazine; in the same year, the authoritative U.S. weekly magazine TIME reported on BioBio for two consecutive times, pointing out that "BioBio is a company with independent research and development capabilities, and is the first biotech company in China to enter the world level". In the same year, Time magazine reported positively on BioBio for two consecutive years, stating that "BioBio is a company with independent R&D capabilities and the ability to develop and produce innovative and cost-effective products. In 2006, BioBio was ranked No. 1 in Deloitte China's top 50 high-tech, high-growth companies, and was selected by the British journal Nature as a globally recognized supplier of recommended microarray products and services, with its HLA genotyping microarray testing system, microarray laser*** focus scanner (VIVOTEK ® LuxScan? 10K), and microarray microarray spotting and production system (VIVOTEK ® LuxScan? 10K), and its microarray microarray spotting and production system (VIVOTEK ® LuxScan? 10K). (VIVOTEK® SmartArrayer? 48 and VIVOTEK® SmartArrayer? 136) were recognized by the Ministry of Science and Technology as National Key New Products. 2007, "Development and Application of Systematic Biochips and Related Instruments" declared by BioBio won the National Technology Invention Award. "In 2008, the National Biochip Standardization Technical Committee was established with the approval of the standardization department of the State Council, with Biochip Beijing National Engineering Research Center as the secretariat unit responsible for the daily management, and Dr. Jing Cheng, the director of the center, as the chairman of the committee.
Biochip will rely on its excellent R&D, production, marketing and service teams, and with its international leading biochip production and service technology platform and high standard quality assurance system, it will provide advanced biochip products and services to customers and partners in the fields of life science research, biological (including food) safety testing, health evaluation and clinical diagnosis, as well as other application areas. We provide advanced high-throughput biochip technology services and industry application solutions to our customers and partners.
Beijing National Engineering Research Center for Biochips (BNERC), approved by the National Development and Reform Commission (former National Development and Planning Commission), is a national research and development institution with the largest scale of product and market sales, the strongest research and development strength, and the largest number of patents applied for and obtained in the field of biochips in China, which was established under the auspices of Biochip of Tsinghua University. Its predecessor was the Biochip Research and Development Center of Tsinghua University, and on September 30, 2000, according to the instruction of the National Development and Reform Commission, Tsinghua University was the main sponsor, and three scientific research institutes, including Huazhong University of Science and Technology, the Chinese Academy of Medical Sciences, and the Academy of Military Medical Sciences, were jointly established as the Beijing National Engineering Research Center for Biochips, which was formally awarded the license in October 2001, and the National Engineering Research Center of Beijing was established by the National Development and Reform Commission of China.
September 2000 to October 2003 in the National Development and Reform Commission, Beijing Municipal Development and Reform Commission's strong support, in the Zhongguancun Science and Technology Park Management Committee of the specific coordination, leased a restaurant in Haidian District, West Tsinghua Road, No. A2, after renovation and decoration of the center's scientific research work as a temporary laboratory and office. The first phase of the center was completed and put into use in October 2003, with a total construction area of 24,000 square meters, including various engineering and scientific research laboratories of international first-class level, GMP ultra-clean workshop for microarray chip fabrication, clean workshop for microfluidic chip pilot test, workshop for the production of life science instrumentation as well as ancillary facilities. The center has first-class scientific research facilities, perfect production conditions, a strong scientific atmosphere and a group of senior researchers who are renowned in the international biochip field, including 10 professors and associate professors, 12 returned senior researchers, and more than 180 researchers of various types, of which 40% have master's degree or above, forming a echelon and a reasonably-structured talent team. The center has been recognized as a national life science and technology talent training base, postdoctoral research station, Beijing major high-tech achievement transformation project, Beijing patent pilot excellent unit and the National High-tech Research and Development Program results of industrialization base.
On May 6, 2010, Hu Jintao, General Secretary of the Central Committee of the People's Republic of China and President of the People's Republic of China, accompanied Kim Jong-il, General Secretary of the Workers' Party of Korea and Chairman of the National Defense Commission, to visit Beijing BioBio Co.